# A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

> **NCT02381886** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 166 (actual)

## Conditions studied

- Advanced Malignancies That Harbor IDHR132 Mutations

## Interventions

- **DRUG:** IDH305

## Key facts

- **NCT ID:** NCT02381886
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-03-06
- **Primary completion:** 2016-12-07
- **Final completion:** 2030-10-31
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02381886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02381886, "A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02381886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*